Zacks: Analysts Anticipate Intec Pharma Ltd (NTEC) Will Announce Earnings of -$0.19 Per Share

Analysts predict that Intec Pharma Ltd (NASDAQ:NTEC) will report ($0.19) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have made estimates for Intec Pharma’s earnings. Intec Pharma reported earnings of ($0.32) per share in the same quarter last year, which suggests a positive year over year growth rate of 40.6%. The firm is expected to issue its next quarterly earnings report on Friday, April 6th.

According to Zacks, analysts expect that Intec Pharma will report full-year earnings of ($1.35) per share for the current year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.89) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Intec Pharma.

Intec Pharma (NASDAQ:NTEC) last issued its earnings results on Wednesday, November 15th. The biotechnology company reported ($0.40) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.06).

Several research analysts have commented on NTEC shares. ValuEngine downgraded Intec Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Zacks Investment Research raised Intec Pharma from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Oppenheimer set a $15.00 target price on Intec Pharma and gave the stock a “buy” rating in a research note on Friday, October 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $11.20.

Intec Pharma (NTEC) opened at $6.50 on Friday. Intec Pharma has a 52 week low of $4.20 and a 52 week high of $9.80.

Large investors have recently added to or reduced their stakes in the company. Sectoral Asset Management Inc bought a new stake in shares of Intec Pharma during the third quarter worth about $3,177,000. Caxton Corp bought a new stake in shares of Intec Pharma during the third quarter worth about $681,000. Pura Vida Investments LLC bought a new stake in shares of Intec Pharma during the third quarter worth about $895,000. Finally, Migdal Insurance & Financial Holdings Ltd. grew its holdings in shares of Intec Pharma by 5.0% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 25,000 shares during the last quarter. Institutional investors own 40.16% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2018/01/27/zacks-analysts-anticipate-intec-pharma-ltd-ntec-will-announce-earnings-of-0-19-per-share.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply